Curcumin

XIAN, China, Oct. 13, 2025 /PRNewswire/ -- Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome and co-loading curcumin liposome raw materials. This technology demonstrates strong potential in enhancing the bioavailability, stability, and synergistic effects of active ingredients, opening up new pathways for health support. Continue Reading Co-loaded Liposomes Show Enhanced Cardiovascular Support — Both CoQ10 and Curcumin liposomes demonstrated superior improvement compared to their conventional forms under experimental conditions. During this R&D process, Natural Field conducted in-depth exploration into the mechanisms of action and efficacy of co-loading CoQ10 liposomes and co-loading curcumin liposomes in areas such as cardiovascular function and gut health. Experimental data shows that the bioabsorption rate of these two co-loading liposomes is 2-10 times higher than that of traditional raw materials. These preliminary data indicate that NFLipo® has more competitive performance in cardiovascular protection, antioxidant, anti-inflammatory, and intestinal barrier regulation. This technological breakthrough brings the following advantages: Higher Bioavailability: Through structural optimization of co-loading liposomes, multiple functional ingredients can be synergistically packaged and stably delivered to target sites more efficiently. Improved Stability: Ordinary liposomes still rely on cellular uptake after extracellular release, which is easily limited by P-glycoprotein (P-gp) efflux, resulting in insufficient intracellular entry efficiency. The new co-loading liposome technology can not only effectively bypass this efflux pathway but also inhibit its activity, thereby significantly improving the bioavailability of ingredients and enhancing their stability during storage and in-vivo transportation. Synergistic Efficacy Potential: The combination of rare ginsenosides with CoQ10 and curcumin not only enhances membrane stability but also co-loads more active ingredients. For example, it meets the synergistic effects of antioxidant support and anti-aging skin care, expanding the functional dimensions of products. Enhanced Customized Development Capabilities: Natural Field has launched a "one-stop liposome service" model, providing customers with personalized customization solutions covering formula design, process optimization, quality control, and large-scale production. As a 20-year supplier in the nutritional health raw material sector, Natural Field has always emphasized both technological innovation and standardized compliance. Currently, its official website clearly lists "co-loading liposomes" as a key product category, and the company has repeatedly highlighted the technology's patent potential and application scenarios in exhibition promotions. To promote industry exchanges and application implementation, Natural Field will participate in the SupplySide Global Exhibition in the U.S. in October 2025, Booth No.6247. At the exhibition, it will showcase its latest co-loading liposome platform and sample products, and conduct in-depth dialogues with global nutritional health raw material suppliers, health supplement manufacturers, and research institutions to explore cooperation opportunities for liposomes in nutritional support and functional raw materials. Through this technological showcase, Natural Field aims to further establish its leading position in the liposome and co-loaded liposome technology field in the international market, provide customers with more efficient, safer, and more differentiated raw material solutions, and drive the entire nutritional health industry toward a higher technological threshold and value chain level. SOURCE Natural Field WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

SUMMIT, N.J., Sept. 29, 2025 /PRNewswire/ -- Vascarta Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for pain and inflammation, announced today the successful completion of its phase 1 clinical trial evaluating VAS-101 (Vasceptor®) for the treatment of osteoarthritis (OA). The study was conducted at Clinical Research Australia in Perth under the direction of Principal Investigator Dr. Adrian Lopresti. Publication and/or presentation of the data is expected in the coming months. The 60-patient, randomized, double-blind, placebo-controlled trial evaluated VAS-101, a proprietary curcumin gel, applied topically every other day for 28 days. The primary objective was to assess the effects of VAS-101 on pain in adults with chronic knee OA. Secondary objectives included evaluating the therapy's impact on safety and tolerability, quality of life, daily function, and the use of analgesics. Dr. Lopresti commented: "When taken orally, curcumin is limited by low absorption, which reduces its therapeutic potential. In this study, VAS-101 administered topically demonstrated promising pain-relieving effects in people with knee osteoarthritis. These findings suggest that Vascarta's Vasporta™ transdermal technology may overcome the bioavailability challenges of oral curcumin, enabling rapid, localized pain relief at much lower doses." About VAS-101 Curcumin is a well-known natural compound with anti-inflammatory and analgesic properties, but its clinical utility has been constrained by poor oral bioavailability. VAS-101 is a highly concentrated, patented curcumin gel formulated using Vascarta's proprietary Vasporta™ transdermal delivery platform, designed to enhance both local and systemic bioavailability. Unmet Need in Knee Osteoarthritis According to the U.S. Centers for Disease Control and Prevention, approximately 21% of U.S. adults were diagnosed with arthritis between 2019 and 2021, with the knee being the most affected joint (World Health Organization). Current treatment options often progress from oral medications to invasive interventions such as intra-articular corticosteroids, hyaluronic acid, platelet-rich plasma, or ultimately, surgical knee replacement. There remains a significant unmet need for non-invasive, effective, and well-tolerated therapies that can provide pain relief for patients, particularly those who cannot tolerate long-term NSAID use. Leadership Perspective "Osteoarthritis is one of the most prevalent and disabling chronic conditions," said Dr. Richard Prince, Vascarta Chairman, CEO & President. "The completion of this Phase 1 trial marks an important milestone in the development of VAS-101 and supports our vision to deliver a safer, effective, and non-invasive alternative for millions of patients worldwide." About Vascarta Vascarta is a clinical-stage pharmaceutical company focused on innovative topical and transdermal delivery of therapeutics for inflammatory conditions, with lead programs in osteoarthritis and sickle cell disease. For more information about Vascarta's clinical programs, please contact: Dr. Richard Prince, Chairman, CEO & President – [email protected] Media Inquiries: David Hymson – [email protected] SOURCE Vascarta Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED